Aeglea Biotherapeutics
United States
About Aeglea Biotherapeutics
87 articles with Aeglea Biotherapeutics
-
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
5/5/2022
Aeglea BioTherapeutics, Inc. announced financial results for the first quarter 2022 and provided program updates.
-
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market
5/5/2022
Aeglea BioTherapeutics, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of registered securities of the Company in a registered direct offering for gross proceeds to Aeglea of approximately $45 million, prior to deducting placement agent fees and estimated offering expenses.
-
Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
4/12/2022
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for pegzilarginase for the treatment of Arginase 1 Deficiency.
-
As Aeglea presents the data this week at the Society for Inherited Metabolic Disorders (SIMD), its stock has responded to both announcements with a strong leap.
-
Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022
4/6/2022
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences.
-
Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting
3/29/2022
Aeglea BioTherapeutics, Inc. today announced poster presentations at two upcoming medical meetings.
-
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
3/8/2022
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced financial results for the fourth quarter and full year 2021, and provided program updates.
-
Aeglea BioTherapeutics Withdraws Public Offering
2/10/2022
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced the withdrawal of the previously announced, proposed public offering.
-
Aeglea BioTherapeutics Announces Proposed Public Offering
2/9/2022
Aeglea BioTherapeutics, Inc. announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.
-
Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency
1/25/2022
Aeglea BioTherapeutics, Inc. today announced that it will host a Key Opinion Leader (KOL) and Patient Caregiver Webinar on Arginase 1 Deficiency on Thursday, February 3, 2022.
-
Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022
1/5/2022
Aeglea BioTherapeutics, Inc. today announced its participation in two investor conferences as follows: Conference: 40th Annual J.P. Morgan Health Care Conference.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
12/6/2021
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study, PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints).
-
Austin, Texas-based Aeglea Biotherapeutics reported what initially appears to be positive outcomes for its Phase III PEACE trial of pegzilarginase in Arginase 1 Deficiency (ARG1-D).
-
Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency
12/5/2021
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the PEACE Phase 3 clinical trial of pegzilarginase in patients with Arginase 1 Deficiency.
-
Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors
11/16/2021
Aeglea BioTherapeutics, Inc. today announced the appointment of Hunter C. Smith to its board of directors.
-
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
11/4/2021
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced financial results for the third quarter ended September 30, 2021, and reviewed recent corporate updates and program highlights.
-
Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics
11/4/2021
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, announced that seven abstracts will be presented at the 14th International Congress of Inborn Errors of Metabolism 2021 being held November 21-23, 2021.
-
Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021
9/1/2021
Aeglea BioTherapeutics, Inc. today announced its participation in the following medical and investor conferences: Investor Meetings 2021 Wells Fargo
-
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
8/5/2021
Aeglea BioTherapeutics, Inc. today announced financial results for the second quarter ended June 30, 2021, and reviewed recent corporate updates and program highlights.